FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2135242557> ?p ?o ?g. }

• W2135242557 abstract "Abstract Background To investigate the expression of Golgi phosphoprotein-3 (GOLPH3) in prostate cancer and determine its prognostic value. Methods Immunohistochemical staining for GOLPH3 was performed on tissue microarrays of 342 prostate patients. The correlation between GOLPH3 expression with its clinicopathologic factors was also analyzed in order to determine its prognostic significance. Results GOLPH3 expression of normal prostate tissues, benign prostate hyperplasia, high-grade prostatic intraepithelial neoplasia, and hormone-dependent prostate cancer (HDPC) did not show any statistically significant difference. In contrast, statistically significant difference was reported in moderate/intense GOLPH3 expression in cases diagnosed with HDPC and castration resistant prostate cancer (CRPC) ( P < 0.0005). Moderate /intense expression of GOLPH3 was associated with androgen independence ( P = 0.012), higher Gleason score ( P = 0.017), bone metastasis ( P = 0.024), higher baseline prostate-specific antigen (PSA) ( P = 0.038), and higher PSA nadir ( P = 0.032). A significantly negative correlation was found between moderate/intense GOLPH3 expression and disease-free survival (DFS) (HR = 0.28, P = 0.012) and overall survival (OS) (HR = 0.42, P = 0.027). Univariated analysis indicated that moderate/intense GOLPH3 expression created a significantly prognostic impact in patients with CRPC. On the other hand, multivariate analysis indicated that GOLPH3 was a significantly independent prognostic factor of DFS ( P = 0.027) in all prostate cancer patients. Conclusions In this study, it was discovered that the overexpression of GOLPH3 is associated with the transition of prostate cancer from hormone sensitive phase to hormone refractory phase. GOLPH3 might be an important prognostic factor of DFS and OS in patients with prostate cancer. In totality, GOLPH3 could be used as a novel candidate in devising a more effective therapeutic strategy to tackle CRPC. Virtual slides The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1452541171722856 ." @default.
• W2135242557 created "2016-06-24" @default.
• W2135242557 creator A5001510007 @default.
• W2135242557 creator A5005488160 @default.
• W2135242557 creator A5005833440 @default.
• W2135242557 creator A5012364593 @default.
• W2135242557 creator A5021669700 @default.
• W2135242557 creator A5046349683 @default.
• W2135242557 creator A5067305709 @default.
• W2135242557 creator A5077119545 @default.
• W2135242557 date "2012-09-24" @default.
• W2135242557 modified "2023-10-06" @default.
• W2135242557 title "Increased expression of Golgi phosphoprotein-3 is associated with tumor aggressiveness and poor prognosis of prostate cancer" @default.
• W2135242557 cites W1580523172 @default.
• W2135242557 cites W1963592300 @default.
• W2135242557 cites W1965732799 @default.
• W2135242557 cites W1965976637 @default.
• W2135242557 cites W1985046929 @default.
• W2135242557 cites W1991062729 @default.
• W2135242557 cites W1994016727 @default.
• W2135242557 cites W1999011921 @default.
• W2135242557 cites W2019480213 @default.
• W2135242557 cites W2042461504 @default.
• W2135242557 cites W2048391838 @default.
• W2135242557 cites W2066086539 @default.
• W2135242557 cites W2074022118 @default.
• W2135242557 cites W2085181480 @default.
• W2135242557 cites W2085690923 @default.
• W2135242557 cites W2087810003 @default.
• W2135242557 cites W2095255377 @default.
• W2135242557 cites W2100138389 @default.
• W2135242557 cites W2104968784 @default.
• W2135242557 cites W2114608969 @default.
• W2135242557 cites W2142335527 @default.
• W2135242557 cites W2152269520 @default.
• W2135242557 cites W2155207531 @default.
• W2135242557 cites W2163583831 @default.
• W2135242557 doi "https://doi.org/10.1186/1746-1596-7-127" @default.
• W2135242557 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3488508" @default.
• W2135242557 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23006319" @default.
• W2135242557 hasPublicationYear "2012" @default.
• W2135242557 type Work @default.
• W2135242557 sameAs 2135242557 @default.
• W2135242557 citedByCount "59" @default.
• W2135242557 countsByYear W21352425572012 @default.
• W2135242557 countsByYear W21352425572013 @default.
• W2135242557 countsByYear W21352425572014 @default.
• W2135242557 countsByYear W21352425572015 @default.
• W2135242557 countsByYear W21352425572016 @default.
• W2135242557 countsByYear W21352425572017 @default.
• W2135242557 countsByYear W21352425572018 @default.
• W2135242557 countsByYear W21352425572019 @default.
• W2135242557 countsByYear W21352425572020 @default.
• W2135242557 countsByYear W21352425572021 @default.
• W2135242557 countsByYear W21352425572022 @default.
• W2135242557 countsByYear W21352425572023 @default.
• W2135242557 crossrefType "journal-article" @default.
• W2135242557 hasAuthorship W2135242557A5001510007 @default.
• W2135242557 hasAuthorship W2135242557A5005488160 @default.
• W2135242557 hasAuthorship W2135242557A5005833440 @default.
• W2135242557 hasAuthorship W2135242557A5012364593 @default.
• W2135242557 hasAuthorship W2135242557A5021669700 @default.
• W2135242557 hasAuthorship W2135242557A5046349683 @default.
• W2135242557 hasAuthorship W2135242557A5067305709 @default.
• W2135242557 hasAuthorship W2135242557A5077119545 @default.
• W2135242557 hasBestOaLocation W21352425571 @default.
• W2135242557 hasConcept C121608353 @default.
• W2135242557 hasConcept C126322002 @default.
• W2135242557 hasConcept C142724271 @default.
• W2135242557 hasConcept C143998085 @default.
• W2135242557 hasConcept C193270364 @default.
• W2135242557 hasConcept C204232928 @default.
• W2135242557 hasConcept C2776235491 @default.
• W2135242557 hasConcept C2777562237 @default.
• W2135242557 hasConcept C2779534503 @default.
• W2135242557 hasConcept C2780192828 @default.
• W2135242557 hasConcept C71924100 @default.
• W2135242557 hasConcept C87874733 @default.
• W2135242557 hasConceptScore W2135242557C121608353 @default.
• W2135242557 hasConceptScore W2135242557C126322002 @default.
• W2135242557 hasConceptScore W2135242557C142724271 @default.
• W2135242557 hasConceptScore W2135242557C143998085 @default.
• W2135242557 hasConceptScore W2135242557C193270364 @default.
• W2135242557 hasConceptScore W2135242557C204232928 @default.
• W2135242557 hasConceptScore W2135242557C2776235491 @default.
• W2135242557 hasConceptScore W2135242557C2777562237 @default.
• W2135242557 hasConceptScore W2135242557C2779534503 @default.
• W2135242557 hasConceptScore W2135242557C2780192828 @default.
• W2135242557 hasConceptScore W2135242557C71924100 @default.
• W2135242557 hasConceptScore W2135242557C87874733 @default.
• W2135242557 hasIssue "1" @default.
• W2135242557 hasLocation W21352425571 @default.
• W2135242557 hasLocation W21352425572 @default.
• W2135242557 hasLocation W21352425573 @default.
• W2135242557 hasLocation W21352425574 @default.
• W2135242557 hasOpenAccess W2135242557 @default.
• W2135242557 hasPrimaryLocation W21352425571 @default.
• W2135242557 hasRelatedWork W1978302297 @default.
• W2135242557 hasRelatedWork W2006720586 @default.
• W2135242557 hasRelatedWork W2019340165 @default.

• next